In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Antihypertensive combination treatment and new European Guidelines

An article from the e-journal of the ESC Council for Cardiology Practice

Current guidelines recommend combination treatment as a means to allow hypertensives to achieve hypertension levels closer to ones of untreated individuals, provided the five main requirements regarding mechanisms of action, effect, protectibililty, side effects and adverse effects are followed. Although fixed combinations help with patient compliance and treatment costs, extemporaneous combinations are flexible and increase physician awareness. Combination treatment is needed to control blood pressure in the majority of patients; It is almost mandatory in diabetic, renal and high risk hypertensive patients and may allow blood pressure targets to be reduced earlier than with monotherapy.


The New European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines on hypertension, issued in 2007, offer an in-depth examination into the problem of blood pressure control during treatment, emphasising the need in current clinical practice for combination drug treatment. Guidelines address in this regard a number of clinically relevant questions, such as:

  1. which are the requirements for a combination drug treatment
  2. when is combination drug treatment needed?
  3. are fixed combinations preferable to extemporaneous ones?
  4. which combinations of priority use?

On these questions (and on the related answers) is focused the present article

Combination treatment allows hypertensives to achieve hypertension levels closer to ones of untreated individuals.

A large number of controlled studies have conclusively shown that treatment of hypertension is beneficial. In virtually all hypertensive conditions, drugs that lower diastolic and/or systolic blood pressure reduce cardiovascular morbidity and mortality (1, 2).
However, this is counterbalanced by the evidence that current management of hypertension is unable to bring the cardiovascular risk of the treated hypertensive patients back to the level of the normotensive individuals (3).

Although several factors are believed to be responsible for this finding, a likely candidate is poor blood pressure control, i.e. the fact that blood pressure levels of treated hypertensives remain, almost invariably, higher than those of normotensive controls. This limitation can be overcome by a therapeutic strategy based on a combination of two or more antihypertensive drugs, which allows to achieve a better blood pressure control (and thus greater cardiovascular protection) in a much larger fraction of hypertensive patients (4). This is one of the reason for which this therapeutic approach has been recommended by the 2007 European Society of Hypertension/European Society of Cardiology Hypertension Guidelines (5).


Combination therapy is successive overall and has five main requirements

Whereas initial monotherapy effectively lowers blood pressure in only a limited fraction of the hypertensive population, combined administration of two or three drugs achieves a successful antihypertensive response in about 80% and 90% of cases, respectively. Combination therapy plays a fundamental role in the overall treatment of hypertension that  is not limited to clinical practice (and thus to the possible incorrect use of single-drug regimens) ; combination treatment with two and three drugs has also been commonly employed to achieve optimal blood pressure in controlled studies. Optimal two-drug combinations are characterised by five main requirements.

  1. First, the drug to be combined should display mechanisms of action that are different but complementary.
  2. Second, they should, when given together, produce an antihypertensive effect that is greater than, or equal to, the sum of the antihypertensive effect of the individual combination components, although an effect that is just greater than that of either drug alone may also be acceptable.
  3. Third, there should also be total or partial summation of their ability to protect against the organs that are damaged by hypertension, e.g. they should produce a regression of left ventricular hypertrophy or a reduction in proteinuria greater than what can be achieved with the individual combination components.
  4. Fourth, they should reciprocally reduce (or at least not increase) their side effects.
  5. Fifth, they should not have untoward (adverse) haemodynamic and humoral effects.


Extemporaneous combinations are flexible and increase physician awareness

Fixed combinations have advantages, but also disadvantages, over the separate administration of the same drugs. Extemporaneous combinations :

  • obviously allow flexible dosing of the components, e.g. the dose of one drug may be increased while keeping the other constant, if this is felt to be useful.
  • facilitate a greater awareness, by the physician, of the constituents of the combination treatment, thus reducing the risk of administering contraindicated drugs and allowing better identification of which drug is responsible for the side effects that may appear during treatment (6).

Except for the flexibility of dosing, these advantages, however, are not in principle incompatible with fixed-dose combinations, provided that doctors receive proper information.

Fixed combinations help with patient compliance and reduce the cost of treatment.

However, fixed combinations have specific advantages. It should be remembered that fixed combinations allow blood pressure control to be achieved with a reduced number of daily tablets compared with extemporaneous combinations, thus simplifying the therapeutic approach.

  • This is of great potential advantage because blood pressure control in the hypertensive population is unsatisfactory, i.e. in only a minority of the hypertensive population is diastolic blood pressure reduced by antihypertensive treatment to 90 mmHg or less (7-8). This is even more evident for systolic blood pressure which is only controlled in a minority of hypertensive individuals, with no trend towards any improvement in the last few years (9). This is due largely to poor compliance with long-term treatment due to a number of factors, among which the complexity of the treatment scheduled.
  • Other favourable features of fixed combination are represented by the reduced treatment cost as compared to the cost of using the same drugs on a separated basis, with further advantages for compliance. This has been acknowledged by the ESH/ESC 2007 Guidelines of hypertension (5), which mention fixed combinations as an asset for antihypertensive treatment and a further means to improve blood pressure control in the hypertensive population.


ESH/ESC 2007 Guidelines (5) make a clear statement on the use of monotherapy and combination drug therapy strategies (Figure). They first emphasise that combination treatment “is needed to control blood pressure in the majority of patients”, making the issue related to the drug of first therapeutic choice less relevant.

They also recognise that combination treatment is almost mandatory in diabetic, renal and high risk hypertensive patients because in all these clinical conditions blood pressure goal is set at 130/80 mmHg or even lower and thus a large blood pressure reduction is oftentimes needed, making the use of single monotherapy not recommended.
Guidelines make a further point in favour of combination therapy, underling the concept that starting treatment with a two-drug combination may allow blood pressure targets to be reduced earlier than with monotherapy. This is of particular importance in high-risk patients, in the light of the evidence provided by the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study that a lack of a prompt blood pressure control may be associated in these individuals with a higher events rate (10)


According to 2007 ESH/ESC Guidelines (5) combination of priority use includes the following:

  • Thiazide diuretic and ACE inhibitor
  • Thiazide diuretic and angiotensin receptor antagonist
  • Calcium antagonist and ACE inhibitor
  • Calcium antagonist and angiotensin receptor antagonist
  • Calcium antagonist and thiazide diuretic
  • Beta-blocker and calcium antagonist (dihydropiridine)

In practical terms the choice of the preferable combination of drugs regimen should be based on a number of factors, including the patient’s age, metabolic and cardiovascular risk profile, the presence of target organ damage, tolerability and side effects of the combinations used.

A final recommendation given by the ESH/ESC 2007 Guidelines refers to the use of low-dose combinations. These should be preferred to high dose combinations because they

  • frequently allow to achieve to an antihypertensive efficacy greater for magnitude than that obtained by high doses and
  • display a much better tolerance profile, which is of key importance for patients compliance to treatment and thus for the clinical success of antihypertensive therapy.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.


1. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of evidence in 1994. J Vasc Med Biol 1993;4:265-271.
2. Struijker-Boudier HA, Ambrosioni E, Holzgreve H, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int J Clin Pract 2007;61:1592-1602.

3. Isles CG, Walker LM, Beevers GD, et al. Mortality in patients of the Glasgow Blood Pressure Clinic.J Hypertens 1986;4:141-156.

4. Mancia G. Blood pressure reduction and cardiovascular outcomes: past, present, and future. Am J Cardiol 2007;100:3J-9J.

5. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).J Hypertens. 2007 ;25:1105-1187.

6. Nesbitt SD. Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction. J Clin Hypertens 2007;9:26-32.

7. Burt VL, Cutler JA, Higgins M, e coll. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-69.

8.  Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206–1252

9. Swales JD. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J 1999;138:231-237.

10. Julius S, Kjeldsen SE, Weber M, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.


Vol6 N°24

Notes to editor

Prof. Guido Grassi
Past Chairman ESC Working Group Hypertension and the Heart
Clinica Medica, Università di Milano-Bicocca, Milan, Italy.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.